

Aspira Women's Health to Present at the A.G.P. Healthcare Showcase on May 21

## **Description**

May 16, 2024 08:00 ET

AUSTIN, Texas, May 16, 2024 (GLOBE NEWSWIRE) — Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the Alliance Global Partner's Healthcare Showcase taking place virtually on Tuesday, May 21, 2024.

## **Presentation Details:**

Date: Tuesday, May 21, 2024

Time: 11:00 am EST

Webcast: Click HERE to register for the conference and view the presentation

Management will be available for one-on-one meetings with investors who are registered for the conference.

## **About Aspira Women's Health Inc.**

Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, Al-powered tests to aid in the diagnosis of gynecologic diseases.

OvaWatch<sup>®</sup> and Ova1Plus<sup>®</sup> are offered to clinicians as OvaSuite<sup>SM</sup>. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is comprised of two FDA-cleared tests, Ova1<sup>®</sup> and Overa<sup>®</sup>, to assess the risk of ovarian malignancy in women planned for surgery.

Our in-development test pipeline is designed to expand our ovarian cancer portfolio and addresses the tremendous need for noninvasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, our OvaMDx<sup>SM</sup> risk assessment is designed to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, EndoCheck<sup>SM</sup> is the first-ever noninvasive test designed to identify endometriomas, one of the most commonly occurring forms of endometriosis. The EndoMDx<sup>SM</sup> test is designed to combine microRNA and protein biomarkers with patient data to identify all endometriosis.



## **Investor Relations Contact:**

Torsten Hombeck, Ph.D. Chief Financial Officer Aspira Women's Health Investors@aspirawh.com